Tradestie Institutional Equity Comparison Engine

RNAZ vs VVOS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

RNAZ Overall Edge

RNAZ Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to TransCode Therapeutics, Inc. Common Stock (RNAZ) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RNAZ trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus VVOS at N/M Forward P/E and -107.9% operating margin (+34.9% YoY). In options structure, RNAZ sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against VVOS sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
RNAZ N/M vs VVOS N/M Fwd P/E
Growth & Margin Winner RNAZ
Op Margin 0.0% vs -107.9% ยท YoY +0.0% vs +34.9%
Momentum & Technical Winner RNAZ
1Y -87.5% vs -97.7% ยท 52W Pos 1% vs 0%
Options & Structure Winner RNAZ
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
RNAZ NASDAQ
TransCode Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.16
-10.77% 1D
Market Cap $22.5M
1M Return -32.36%
1Y Return -87.45%
Forward P/E N/M
Unified AI Score
40.5 / 100 SELL
Tech 25.0 Fund 47.0 Flow 50.0 Mom 55.0
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
1M Return -59.25%
1Y Return -97.71%
Forward P/E N/M
Unified AI Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RNAZ -87.45% VVOS -97.71% Spread: +10.61 pp (RNAZ Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RNAZ TTM Op. Margin: 0.0% VVOS TTM Op. Margin: -107.9%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RNAZ vs VVOS. Trailing 12-month operating profitability (RNAZ 0.0% vs VVOS -107.9%) and valuation multiples (RNAZ N/M vs VVOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RNAZ (7) vs VVOS (1)
Institutional Metric RNAZ VVOS Criterion Row Winner
Market Capitalization Scale $22.5M $1.9M Larger Scale RNAZ
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +34.9% Higher Growth VVOS
Operating Margin (TTM) Profitability 0.0% -107.9% Higher Margin RNAZ
Net Profit Margin Profitability 0.0% -121.8% Higher Margin RNAZ
Return on Equity (ROE) Capital Efficiency -866.1% -8585.3% Higher ROE RNAZ
52-Week Range Position Momentum 1% ($1โ€“$13) 0% ($0โ€“$3) Stronger Trend RNAZ
Beta / 30D Volatility Risk Regime 1.27ฮฒ ยท 87% Vol 1.70ฮฒ ยท 111% Vol Lower Realized Risk RNAZ
Unified Institutional Score Composite Signal 40.5 / 100 (SELL) 36.4 / 100 (SELL) Higher Composite RNAZ

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RNAZ vs VVOS Buy Guide
RNAZ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RNAZ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
VVOS BREAKDOWN
113d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live VVOS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RNAZ nor VVOS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.